[Skip to Navigation]
February 14, 2017

Sublingual Immunotherapy for Allergic Rhinitis: Is 2-Year Treatment Sufficient for Long-term Benefit?

Author Affiliations
  • 1University of Miami Miller School of Medicine at Holy Cross Hospital, Ft Lauderdale, Florida
JAMA. 2017;317(6):591-593. doi:10.1001/jama.2017.0128

Allergen-specific immunotherapy (AIT) is a desensitizing and potentially curative therapy that has been used since 1911 to treat allergic rhinitis and asthma.1 Immunotherapy involves repeated administration of the identified allergen(s) over time with the goal of inducing sustained allergen-specific tolerance. The proportion of patients treated with AIT who do not maintain sustained allergen-specific tolerance varies from 0% to 55%, depending on factors including type of allergen, treatment duration, and the definition of relapse.2